论文部分内容阅读
目的:了解某院肿瘤患者升白细胞药的使用情况,规范该院肿瘤患者升白细胞药的使用。方法:采用回顾性分析方法,调查2014年1~12月某院诊断为恶性肿瘤并开具升白细胞药的患者病历579份,收集患者的基本信息、化疗情况、化疗后骨髓抑制情况和升白细胞药使用情况等信息,对升白细胞治疗的药物种类、给药时机、给药剂量、给药频次、使用疗程、联合用药以及溶媒的选择进行分析。结果:该院升白细胞药物以口服制剂为主;579例病例中合理用药病历414例,占71.50%,不合理用药病历165份,占28.50%,其中用药剂量和疗程基本符合要求,而不合理病例中主要以品种和给药时机不适宜为主,分别为42.42%和27.88%,其次为重复给药和联合用药不适宜,分别为13.33%和12.73,溶媒选择不适宜发生率较低,为3.64%。结论:该院肿瘤患者升白细胞药的使用有待规范,临床医师需加强升白细胞药应用知识的学习,合理使用该类药物。
OBJECTIVE: To understand the use of leukocyte drugs in patients with cancer in a hospital and to regulate the use of leukocyte drugs in patients with cancer in the hospital. Methods: A retrospective analysis was conducted to investigate the medical records of 579 patients diagnosed as malignant tumor and receiving leukocyte drug in a hospital from January to December in 2014. The patients’ basic information, chemotherapy, bone marrow suppression after chemotherapy and leukocyte drug Usage and other information on the type of drug leukocyte treatment, timing of administration, dosage, frequency of administration, use of treatment, combination therapy and the choice of vehicle for analysis. Results: There were 414 patients (accounting for 71.50%) of rational use of medical records in 579 cases, 165 cases of unreasonable medical records, accounting for 28.50%, of which the dosage and course of treatment were basically in line with the requirements, but not reasonable The main cases of the species and the timing of administration is not appropriate, respectively, 42.42% and 27.88%, followed by repeated administration and combination of inappropriate, respectively, 13.33% and 12.73, the lower the incidence of inappropriate choice of solvent was 3.64%. Conclusion: The use of leukocyte drugs in patients with cancer needs to be standardized. Clinicians need to learn more about the application of leukocyte drugs and use such drugs reasonably.